Functional Neuromodulation Announces CEO Leadership Transition

January 25, 2019 - – Todd Langevin named CEO

  • Analysis of Phase 2 Study Demonstrates Acceptable Safety, Increased Glucose Metabolism, and Suggests Clinical Benefit in Mild Alzheimer’s Disease Patients
  • DBSf Clinical Development Program to Proceed to Phase 3

Minneapolis, MN – January 25, 2019 – Functional Neuromodulation Ltd. (“FNM or the “Company”), a medical device company focused on bringing to market DBSf, an implantable deep brain stimulation (DBS) therapy targeting the fornix for mild Alzheimer’s disease patients, announces that Mr. Todd Langevin will succeed Mr. Vincent Owens as Chief Executive Officer with effect from January 25, 2019.  Mr. Owens will remain deeply involved in the Company as Executive Chairman. 
Mr. Langevin most recently served as President and Chief Operating Officer of FNM since its formation in 2011.  Prior to joining FNM, Mr. Langevin held senior leadership roles at medical device companies including CVRx and Medtronic. His prior roles during 20-year career at Medtronic included Vice President & General Manager of Medtronic’s DBS Movement Disorders Business and an earlier role as European Business Director, Neuromodulation. 
Mr. Owens, Executive Chairman of FNM commented: “Todd has been instrumental in leading the company through the ADvance I study, CE Mark approval, and IDE approval of the ADvance II pivotal study of DBSf.  FNM’s investors, employees and I have great confidence in Todd’s leadership and we look forward to beginning enrollment in ADvance II.”

About Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral disturbances that eventually result in a person’s inability to perform daily activities.  It is estimated that 25 million individuals are living with AD worldwide.

About Functional Neuromodulation Ltd.

Functional Neuromodulation Ltd. (FNM), founded in 2010 in Toronto by Dr. Andres Lozano, is advancing deep brain stimulation therapy to improve the lives of people with mild Alzheimer’s disease. In partnership with Boston Scientific, FNM is developing the use of deep brain stimulation of the fornix (DBS-f) to drive neural activity and modulate the memory circuit in patients with mild Alzheimer’s disease. The company completed the ADvance I Study, a multi-center Phase II randomized clinical trial of DBS-f, and it has initiated the ADvance II study, a pivotal study of DBSf in mild Alzheimer’s disease in the U.S., Europe, and Canada. More information about the company can be found at

About the ADvance II clinical study:

ADvance II is an FDA IDE approved clinical study ( Identifier: NCT03622905) of DBSf in mild Alzheimer’s disease, being conducted at approximately 15 centers in the U.S. and Canada and 6 centers in Germany.



Robyn Moxon, Marketing/Public Relations
Functional Neuromodulation, Ltd
200 South Sixth Street Suite 3400
Minneapolis, MN 55402

Press releases

DBS and Alzheimer’s
in the News

Functional Neuromodulation, Ltd.
200 South Sixth Street Suite 3400 | Minneapolis, MN 55402 | | 1-866-296-4040
© Functional Neuromodulation Ltd. All rights reserved.